242 filings
Page 4 of 13
8-K
slu7e
7 Jun 22
Forte Biosciences, Inc. Announces the Appointment of
9:03am
8-K
qfcxes33 nryln6iktv
2 Jun 22
Submission of Matters to a Vote of Security Holders
4:05pm
DEFA14A
bmujadpfgmj
19 May 22
Additional proxy soliciting materials
4:05pm
8-K
00tvuz04
16 May 22
Forte Biosciences, Inc. Announces First Quarter 2022 Results and Provides Business Update
9:01am
8-K
oaog6wk o0h140r00
31 Mar 22
Entry into a Material Definitive Agreement
8:57pm
424B5
73f 21yyb
31 Mar 22
Prospectus supplement for primary offering
8:55pm
8-K
knucrw
18 Mar 22
Departure of Directors or Certain Officers
9:01am
8-K
m3zus4 jjx6d
2 Feb 22
Termination of a Material Definitive Agreement
4:35pm
8-K
nkonqznj406wrz00fzc
2 Sep 21
Clinical Trial of FB-401 for the Treatment of Atopic Dermatitis Fails to Meet Statistical Significance
4:05pm
EFFECT
xqk3as
8 Jun 21
Notice of effectiveness
12:15am
8-K
lien1osdj1 m88yesf
4 Jun 21
Departure of Directors or Certain Officers
4:05pm
UPLOAD
99tc5zpt
3 Jun 21
Letter from SEC
12:00am
CORRESP
nupv byl8f
3 Jun 21
Correspondence with SEC
12:00am